Literature DB >> 21224746

Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced MRI in detection of recurrent glioma.

Amburanjan Santra1, Punit Sharma, Rakesh Kumar, Chandrashekhar Bal, Atin Kumar, Pramod Kumar Julka, Arun Malhotra.   

Abstract

BACKGROUND: Differentiation between recurrence and radiation necrosis in patients with glioma is crucial, as the two entities have completely different management and prognosis. The purpose of this study was to compare the efficacies of glucoheptonate (GHA) single photon emission computed tomography (SPECT) and contrast-enhanced MRI in the detection of recurrent glioma.
METHODS: Eighty-five patients with histopathologically proven glioma with a clinical suspicion of recurrence were evaluated using Tc-99m GHA SPECT and MRI. A combination of clinical follow-up, repeat imaging and/or biopsy (when available) was taken as a gold standard.
RESULTS: On the basis of the gold standard, 56 patients were positive and 29 were negative for tumour recurrence. The sensitivity, specificity and accuracy of GHA SPECT were 86.5, 96.5 and 89.4% respectively, whereas those of MRI were 94.6, 24.1 and 70.5% respectively. On subgroup analysis GHA SPECT had similar sensitivities with a much higher specificity than MRI across all grades. Thirty patients had intermodality discordance, with GHA SPECT being correct in 23 of them.
CONCLUSION: GHA SPECT seems to be a highly sensitive and specific imaging modality for the detection of recurrent gliomas compared with contrast-enhanced MRI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21224746     DOI: 10.1097/MNM.0b013e328341c3e9

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

Review 1.  Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?

Authors:  Ashish H Shah; Brian Snelling; Amade Bregy; Payal R Patel; Danoushka Tememe; Rita Bhatia; Evelyn Sklar; Ricardo J Komotar
Journal:  J Neurooncol       Date:  2013-01-24       Impact factor: 4.130

Review 2.  Use of 99m-technetium-glucoheptonate as a tracer for brain tumor imaging: An overview of its strengths and pitfalls.

Authors:  Amburanjan Santra; Rakesh Kumar; Punit Sharma
Journal:  Indian J Nucl Med       Date:  2015 Jan-Mar

3.  Evaluation of Technetium-99m glucoheptonate single photon emission computed tomography for brain tumor grading.

Authors:  Syed Shafiq Alam; Syed Junaid; Syed Mushtaq Ahmed
Journal:  Asian J Neurosurg       Date:  2016 Apr-Jun

Review 4.  Indian data on central nervous tumors: A summary of published work.

Authors:  Archya Dasgupta; Tejpal Gupta; Rakesh Jalali
Journal:  South Asian J Cancer       Date:  2016 Jul-Sep

5.  Differentiation of Treatment-Related Effects from Glioma Recurrence Using Machine Learning Classifiers Based Upon Pre-and Post-Contrast T1WI and T2 FLAIR Subtraction Features: A Two-Center Study.

Authors:  Xin-Yi Gao; Yi-Da Wang; Shi-Man Wu; Wen-Ting Rui; De-Ning Ma; Yi Duan; An-Ni Zhang; Zhen-Wei Yao; Guang Yang; Yan-Ping Yu
Journal:  Cancer Manag Res       Date:  2020-05-07       Impact factor: 3.989

6.  Tc-99m Glucoheptonate Single Photon Emission Computed Tomography-Computed Tomography for Detection of Recurrent Glioma: A Prospective Comparison with N-13 Ammonia Positron Emission Tomography-Computed Tomography.

Authors:  Bangkim Chandra Khangembam; Abhinav Singhal; Rajeev Kumar; Chandrasekhar Bal
Journal:  Indian J Nucl Med       Date:  2019 Apr-Jun

7.  Radiological diagnosis of brain radiation necrosis after cranial irradiation for brain tumor: a systematic review.

Authors:  Motomasa Furuse; Naosuke Nonoguchi; Kei Yamada; Tohru Shiga; Jean-Damien Combes; Naokado Ikeda; Shinji Kawabata; Toshihiko Kuroiwa; Shin-Ichi Miyatake
Journal:  Radiat Oncol       Date:  2019-02-06       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.